Table 1.
Sequence of clinical events
| Event sequence | WBC (×10 9 ) | Eosinophils in PB (%, AEC) | Eosinophils in BM (%) | Blasts in BM (%) | Diagnosis | Intervention | Disease status |
|---|---|---|---|---|---|---|---|
| Initial presentation |
44.6 |
1, 0.45 |
1 |
7 |
CMML-1 |
SGI-110 |
Refractory |
| After 2 months |
65.1 |
9, 5.8 |
5 |
4 |
CMML-1 |
SGI-110 |
Progression |
| After 1 month |
126 |
11, 13.8 |
16 |
12 |
Myelodysplastic/myeloproliferative neoplasm with eosinophilia, and PDGFRA rearrangement |
Fludarabine + Cytarabine |
Progression |
| After 1 month | 6.4 | 1, 0.06 | 1 | 26 | AML with PDGFRA rearrangement | Imatinib (with Idarubicin + Cutarabine) | Remission |
WBC: white blood cells, PB: peripheral blood, AEC: absolute eosinophil count, BM: bone marrow, CMML: chronic myelomonocytic leukemia, AML: acute myeloid leukemia.